SSGJ-707
Based on 1 Customer Validation
SSGJ-707 (PF-08634404) is a bispecific antibody targeting VEGF and PD-1. SSGJ-707 exerts dual anti-tumor effects by neutralizing VEGF and blocking the PD-1 signaling pathway. SSGJ-707 can be combined with platinum-based chemotherapy to inhibit advanced non-small cell lung cancer (NSCLC), and its inhibitory effect is not limited by PD-L1 expression levels. In the HARMONi-2 trial, the objective response rate of SSGJ-707 correlates with the PD-L1 tumor proportion score, and the incidence of grade ≥3 adverse events is comparable to that of Inetetamab (HY-P99969). SSGJ-707 is being extensively investigated for a variety of malignancies including advanced NSCLC, colorectal cancer and small cell lung cancer.
For research use only. We do not sell to patients.
- Purity : ≥99.0%
- Molecular Weight:241.16 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All VEGFR Isoforms
More
Biological Activity
Description
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
PD-1 & VEGF
In Vitro
SSGJ-707 (PF-08634404) inhibits PD-1-mediated T cell dysfunction and restores the anti-tumor immune activity of T cells in the tumor microenvironment[4].
SSGJ-707 (PF-08634404) blocks VEGF-A-mediated tumor angiogenesis and reverses the immunosuppressive microenvironment induced by VEGF[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG4
Application
ELISA, FACS, Functional assay
Verified Bioactivity
-
Flow Cytometry analysis of Hela cells labelling PD-1 (red) with SSGJ-707 (anti-PD-1) (HY-P991628). Cells were stained with the primary antibody at 1/200 dilution for an hour at 4℃. Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG4 (S228P) kappa (HY-P99003, blue) was used as the isotype control. -
Flow Cytometry analysis of K562 cells labelling VEGF (red) with SSGJ-707 (HY-P991628). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. Then cells were stained with the primary antibody at 1/200 dilution for an hour at 4℃. Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG4 (S228P) kappa (HY-P99003, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black). -
Immobilized Human PD-1 Protein, His tag can bind SSGJ-707. The EC50 for this effect is 43.15 ng/mL. -
Immobilized rhVEGF can bind SSGJ-707. The EC50 for this effect is 74.03 ng/mL.
Chemical Information
-
Appearance Liquid
-
Molecular Weight 241.16 kDa
-
Color Colorless to light yellow
-
SMILES
[SSGJ-707]
-
Synonyms
PF-08634404
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
Purity & Documentation
-
Data Sheet (260 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)